These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 31121559)
1. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors. Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290 [TBL] [Abstract][Full Text] [Related]
5. Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity. Aly RM; Serya RAT; El-Motwally AM; Esmat A; Abbas S; Abou El Ella DA Bioorg Chem; 2017 Dec; 75():368-392. PubMed ID: 29096097 [TBL] [Abstract][Full Text] [Related]
6. Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors. Ansari AJ; Joshi G; Yadav UP; Maurya AK; Agnihotri VK; Kalra S; Kumar R; Singh S; Sawant DM Bioorg Chem; 2019 Dec; 93():103314. PubMed ID: 31590041 [TBL] [Abstract][Full Text] [Related]
7. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents. Yassen AS; Elshihawy HE; Said MM; Abouzid KA Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927 [TBL] [Abstract][Full Text] [Related]
8. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses. Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents. Yang X; Hou Z; Wang D; Mou Y; Guo C Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Zhang B; Liu Z; Xia S; Liu Q; Gou S Eur J Med Chem; 2021 Apr; 216():113300. PubMed ID: 33640672 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017 [TBL] [Abstract][Full Text] [Related]
14. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
15. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
18. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study. Kumar CBP; Raghu MS; Prathibha BS; Prashanth MK; Kanthimathi G; Kumar KY; Parashuram L; Alharthi FA Bioorg Med Chem Lett; 2021 Jul; 44():128118. PubMed ID: 34015505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]